EA018630B1 - Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции - Google Patents

Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции Download PDF

Info

Publication number
EA018630B1
EA018630B1 EA201001722A EA201001722A EA018630B1 EA 018630 B1 EA018630 B1 EA 018630B1 EA 201001722 A EA201001722 A EA 201001722A EA 201001722 A EA201001722 A EA 201001722A EA 018630 B1 EA018630 B1 EA 018630B1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
peptide
present
cyclic
cyclic peptide
Prior art date
Application number
EA201001722A
Other languages
English (en)
Russian (ru)
Other versions
EA201001722A1 (ru
Inventor
Йи-Цунь Ши
Шубх Д. Шарма
Вей Янг
Синь Чэнь
Original Assignee
Палатин Текнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Палатин Текнолоджиз, Инк. filed Critical Палатин Текнолоджиз, Инк.
Publication of EA201001722A1 publication Critical patent/EA201001722A1/ru
Publication of EA018630B1 publication Critical patent/EA018630B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA201001722A 2008-06-09 2009-06-08 Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции EA018630B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5991008P 2008-06-09 2008-06-09
PCT/US2009/046571 WO2009152079A1 (en) 2008-06-09 2009-06-08 Melanocortin receptor-specific peptides for treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
EA201001722A1 EA201001722A1 (ru) 2011-08-30
EA018630B1 true EA018630B1 (ru) 2013-09-30

Family

ID=41417081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001722A EA018630B1 (ru) 2008-06-09 2009-06-08 Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции

Country Status (14)

Country Link
US (2) US8487073B2 (enExample)
EP (1) EP2300036B1 (enExample)
JP (1) JP5628796B2 (enExample)
KR (1) KR101687037B1 (enExample)
CN (1) CN102131514B (enExample)
AU (1) AU2009257631B2 (enExample)
BR (1) BRPI0909947A2 (enExample)
CA (1) CA2727317C (enExample)
EA (1) EA018630B1 (enExample)
IL (1) IL209867A (enExample)
MX (1) MX2010013436A (enExample)
NZ (1) NZ590254A (enExample)
WO (1) WO2009152079A1 (enExample)
ZA (1) ZA201009165B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
CN102702330B (zh) * 2012-03-01 2015-04-01 张嘎 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物
WO2013138340A1 (en) * 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
ES2701444T5 (es) * 2012-11-05 2024-05-21 Palatin Technologies Inc Usos de bremelanotida en una terapia para la disfunción sexual femenina
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PT3356386T (pt) 2015-09-30 2024-05-17 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados à via do receptor da melanocortina-4
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
JP7735282B2 (ja) * 2020-02-03 2025-09-08 パラティン テクノロジーズ， インコーポレイテッド 逆アミド結合を持つメラノコルチン受容体に特異的な環状ペプチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138136A1 (en) * 2000-06-28 2004-07-15 Sharma Shubh D Cyclic peptide compositions and methods for treatment of sexual dysfunction
US20070027091A1 (en) * 2003-09-30 2007-02-01 Novo Nordisk A/S Novel Melanocortin Receptor Agonists
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
KR100519201B1 (ko) 1999-03-29 2005-10-06 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
EP1251865A1 (en) 2000-01-18 2002-10-30 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
CN100491396C (zh) 2000-08-30 2009-05-27 霍夫曼-拉罗奇有限公司 选择性环肽
HUP0303085A2 (hu) 2000-09-27 2003-12-29 The Procter & Gamble Co. Melanokortin receptor ligandumok és ezeket tartalmazó gyógyszerkészítmények
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
CA2453027A1 (en) 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
ES2274201T3 (es) * 2002-01-23 2007-05-16 Eli Lilly And Company Agonistas del receptor de melanocortina.
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20060122121A1 (en) 2002-11-14 2006-06-08 Lipton James M Modified alpha-MSH peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
US20050101535A1 (en) 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
AU2004251616A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1689349B9 (en) 2003-11-24 2014-02-26 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
US20070155660A1 (en) 2003-12-10 2007-07-05 Marsh Donald J Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
CA2557739A1 (en) 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
US8569234B2 (en) 2004-10-08 2013-10-29 Clinuvel Pharmaceuticals Limited Compositions and methods for including melanogenesis in a subject
KR101255140B1 (ko) 2004-10-25 2013-04-22 얀센 바이오테크 인코포레이티드 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도
CN101052647A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新的肽类
JP2008519009A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
CN101052648A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
EP1809667A1 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
JP2008533101A (ja) 2005-03-17 2008-08-21 ノボ ノルディスク アクティーゼルスカブ 肥満の治療において使用するための化合物
AU2006253733A1 (en) 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Backbone cyclized melanocortin stimulating hormone (alpha S ) analogs
JP4734411B2 (ja) 2005-07-08 2011-07-27 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンド
US8349797B2 (en) 2005-07-08 2013-01-08 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
WO2007027574A2 (en) 2005-08-29 2007-03-08 Palatin Technologies, Inc. Cyclic peptide isolation by spray drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
JP2010516653A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
CA2727317C (en) * 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US20090305960A1 (en) 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138136A1 (en) * 2000-06-28 2004-07-15 Sharma Shubh D Cyclic peptide compositions and methods for treatment of sexual dysfunction
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
US20070027091A1 (en) * 2003-09-30 2007-02-01 Novo Nordisk A/S Novel Melanocortin Receptor Agonists

Also Published As

Publication number Publication date
KR20110040819A (ko) 2011-04-20
EP2300036B1 (en) 2017-04-05
CN102131514B (zh) 2014-08-20
AU2009257631A1 (en) 2009-12-17
MX2010013436A (es) 2011-06-21
IL209867A0 (en) 2011-02-28
NZ590254A (en) 2012-07-27
WO2009152079A1 (en) 2009-12-17
CA2727317A1 (en) 2009-12-17
EP2300036A4 (en) 2012-01-18
JP2011522839A (ja) 2011-08-04
US20110065652A1 (en) 2011-03-17
US8729224B2 (en) 2014-05-20
KR101687037B1 (ko) 2016-12-15
EA201001722A1 (ru) 2011-08-30
ZA201009165B (en) 2012-03-28
IL209867A (en) 2015-08-31
AU2009257631B2 (en) 2014-07-24
CN102131514A (zh) 2011-07-20
JP5628796B2 (ja) 2014-11-19
US20130288987A1 (en) 2013-10-31
CA2727317C (en) 2015-02-17
BRPI0909947A2 (pt) 2017-06-27
US8487073B2 (en) 2013-07-16
EP2300036A1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
EA018630B1 (ru) Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
CN102458436B (zh) 黑皮质素受体特异性肽
US9580466B2 (en) Melanocortin-1 receptor-specific linear peptides
KR20120123654A (ko) 멜라노코르틴-1 수용체 특이적 고리형 펩티드
US9273098B2 (en) Lactam-bridged melanocortin receptor-specific peptides
US8247530B2 (en) N-alkylated cyclic peptide melanocortin agonists
WO2016168388A2 (en) Therapies for obesity, diabetes and related indications
US12281180B2 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
KR20220137042A (ko) 역 아미드 결합 멜라노코르틴 수용체 특이적 고리형 펩티드
WO2025254699A1 (en) Orally deliverable non-naturally occurring melanocortin analogs and associated methods for modulating weight gain
CN1988915A (zh) 用于性功能障碍的多药治疗
WO2025245288A1 (en) Non-naturally occurring melanocortin analogs and uses thereof
WO2025151135A1 (en) Methods of treating cancer and/or chemotherapy related conditions using non-naturally occurring melanocortin analogs
WO2025175224A1 (en) Orally deliverable non-naturally occurring melanocortin analogs and associated methods for modulating weight gain
WO2025123056A1 (en) Non-naturally occurring melanocortin analogs and associated methods

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU